Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging securities fraud and unlawful business practices related to the company's New Drug Application for aficamten [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Cytokinetics and certain officers or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until November 17, 2025, to request to be appointed as Lead Plaintiff if they purchased Cytokinetics securities during the Class Period [2]. Group 2: FDA Interaction and Stock Impact - On March 10, 2025, Cytokinetics disclosed that the FDA would not convene an advisory committee meeting for aficamten's NDA [4]. - The FDA extended the action date for aficamten's NDA from September 26, 2025, to December 26, 2025, due to the need for a Risk Evaluation and Mitigation Strategy (REMS) that was not included in the original NDA [4]. - Following the news, Cytokinetics' stock price fell by $5.57 per share (12.98%) to close at $37.35 on May 2, 2025 [5]. - On May 6, 2025, CEO Robert I. Blum acknowledged that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS [5]. - After this acknowledgment, the stock price fell by $2.70 per share (7.36%) to close at $33.97 on May 6, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. regarding allegations of securities fraud and unlawful business practices following disappointing clinical trial results [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether aTyr and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until December 8, 2025, to request appointment as Lead Plaintiff if they purchased aTyr securities during the Class Period [2]. Group 2: Clinical Trial Results - On September 15, 2025, aTyr announced that the EFZO-FIT study, a Phase 3 trial for intravenous Efzofitimod in pulmonary sarcoidosis patients, did not meet its primary endpoint [4]. - Following the announcement of the trial results, aTyr's stock price fell by $5.01 per share, or 83.17%, closing at $1.01 per share [5]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [6].

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether LifeMD and certain of its officers ...

Core Viewpoint - A class action lawsuit has been filed against PubMatic, Inc. regarding allegations of securities fraud and unlawful business practices [2]. Group 1: Class Action Details - Investors are encouraged to contact Pomerantz LLP if they purchased PubMatic securities during the Class Period, with a deadline to apply as Lead Plaintiff by October 20, 2025 [2]. - A copy of the Complaint related to the class action can be obtained from Pomerantz's website [2]. Group 2: Financial Performance and Impact - On August 11, 2025, PubMatic reported a reduction in ad spend from a top demand side platform (DSP) partner, which negatively impacted its financial outlook [4]. - The CEO of PubMatic indicated that a significant number of clients had shifted to a new platform, creating challenges for the company [4]. - Following the announcement, PubMatic's stock price dropped by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. regarding allegations of securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that aTyr and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until December 8, 2025, to request to be appointed as Lead Plaintiff if they purchased aTyr securities during the Class Period [2]. Group 2: Company Performance - On September 15, 2025, aTyr announced that its EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price [4]. - Following the announcement, aTyr's stock price fell by $5.01 per share, or 83.17%, closing at $1.01 per share [5]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [6].

Core Insights - Braskem S.A. is a leading petrochemical company based in Brazil, specializing in thermoplastic resins and other petrochemical products, with a global presence and competition from major players like Dow Chemical and BASF [1] Financial Performance - On October 15, 2025, Grupo Santander downgraded Braskem's stock from "Neutral" to "Underperform," with the stock priced at $2.54, reflecting concerns about the company's financial health and strategic direction [2][6] - Following an announcement on September 26, 2025, regarding the exploration of financial alternatives, Braskem's ADR price dropped by 14.71%, closing at $2.61, indicating investor concerns [3][6] - Despite the downgrade and ongoing investigation, Braskem's stock showed resilience, currently priced at $2.54, a 1.6% increase from the previous day, with a market cap of approximately $1.01 billion and a trading volume of 526,021 shares [4][6] Stock Volatility - Over the past year, Braskem's stock has experienced significant volatility, reaching a high of $6.56 and a low of $2.32, reflecting challenges in optimizing its capital structure and addressing legal concerns [5][6]

Core Viewpoint - A class action lawsuit has been filed against Marex Group Plc, alleging securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that Marex and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until December 8, 2025, to request to be appointed as Lead Plaintiff if they purchased Marex securities during the Class Period [2]. Group 2: Financial Allegations - A report by NINGI Research accused Marex of engaging in a multi-year accounting scheme involving opaque off-balance-sheet entities and misleading disclosures to conceal losses and inflate profits [4]. - Following the release of the report, Marex's stock price dropped by $2.33 per share, or 6.19%, closing at $35.31 per share on August 5, 2025 [4]. Group 3: Legal Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud [5].

Group 1 - Fortress Biotech Inc. is under investigation by Pomerantz LLP for potential securities fraud or unlawful business practices involving its officers and/or directors [1] - On October 1, 2025, Fortress and its subsidiary, Cyprium Therapeutics, received a Complete Response Letter (CRL) from the U.S. FDA regarding the New Drug Application for CUTX-101, citing cGMP deficiencies at the manufacturing facility [1] - Following the announcement of the CRL, Fortress's stock price dropped by $1.14 per share, representing a decline of 30.81%, closing at $2.56 per share on the same day [1] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [2] - The firm has a legacy of recovering multimillion-dollar damages awards for class members over its 85 years of operation [2]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Palantir Technologies Inc. regarding potential securities fraud or unlawful business practices [1] - An internal U.S. Army memo reported that Palantir's NGC2 platform is considered "very high risk" due to security vulnerabilities, leading to a significant drop in Palantir's stock price [1] Group 1: Investigation Details - The investigation focuses on whether Palantir and its officers or directors have engaged in securities fraud or other unlawful business practices [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [1] Group 2: Stock Market Impact - Following the news of the security vulnerabilities, Palantir's stock price fell by $13.98 per share, or 7.47%, closing at $173.07 per share on October 3, 2025 [1]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Larimar Therapeutics, Inc. following a significant stock price drop after the release of clinical trial data [1] Group 1: Company Overview - Larimar Therapeutics, Inc. is publicly traded on NASDAQ under the ticker LRMR [1] - The company is currently conducting a long-term open-label study on Nomlabofusp for treating Friedreich's Ataxia [1] Group 2: Recent Developments - On September 29, 2025, Larimar announced "positive" data from its ongoing study, but also reported seven cases of anaphylaxis among participants [1] - Following the announcement, Larimar's stock price decreased by $1.72, representing a 33.66% decline, closing at $3.38 per share [1]